MIROCALS consortium is formed by 12 organisations in the EU to conduct a phase II Proof of Concept / Proof of Mechanism Clinical Trial aiming to test the interleukin-2 (IL-2) as treatment for amyotrophic lateral sclerosis (ALS).

The science of the project is coordinated by Dr Gilbert Bensimon of the University Hospital of Nimes (France) which is the trial sponsor, and Professor P. Nigel Leigh of the Brighton and Sussex Medical School (UK).

Around them, the MIROCALS consortium brings together a strong partnership of: leading scientists and clinicians from six European laboratories in France, Italy, Sweden and UK; two clinical research organisations for professional biobanking and trial regulatory-compliant monitoring; the MND Association one of the most active patients’ associations in the field of neurodegeneration worldwide and an EU project management company.

MIROCALS is a 4-year collaborative research project started in September 2015 and supported by the European Union’s Horizon 2020 research and innovation Programme.


Logo CHU Inserm Transfert Logo

University Hospital of Nimes
Nîmes, France

Inserm Transfert
Paris, France

ICON logo jpg original Généthon EN Q

ICON plc

Evry, France

HumanitasRH 1498139 ny logo en high

Humanitas Research Hospital
Milan, Italy

University of Gothenburg

US small pos k tuoslogo key

University of Sussex

University of Sheffield

kingslondon queen mary

King's College London
London, UK

Queen Mary University
London, UK


Motor Neurone Disease Association

WGK Consultancy Ltd


End of trial recruitment phase this autumn

The MIROCALS (Modifying Immune Response and Outcomes in ALS) Clinical Trial is still on-going, with recruitment continuing until the end of September 2019.

Read more

Charities and Patient Associations rally around MIROCALS to show their support

Clinical trials are expensive to run and with several more neurology clinics taking part, ...

Read more

Will Brexit impact on MIROCALS?

As with everything else affected by Brexit, there are probably more questions than answers!

Read more

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 633413.